A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease (ENVISION Study)
A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (≥50 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (≥50 Years of Age) Receiving 1 Dose
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Age-related macular degeneration (AMD) is the leading cause of vision loss among older adults, affecting approximately 2.5 million Canadians. The condition progressively affects the macula, a part of the retina that plays a crucial role in our vision precision. With time, AMD can result in blurred vision or a blind spot in the centre of a person's field of vision.
